PHOENIX, Ariz. May 12, 2010 Dr. James Bogenberger has been awarded a 3-year, $150,000 postdoctoral fellowship by the American Cancer Society to research acute myeloid leukemia at the Translational Genomics Research Institute (TGen).
Acute myeloid leukemia (AML), the most common and deadliest acute adult leukemia, is a malignancy in granulocytes or monocytes, the body's white blood cells that battle infections.
Dr. Bogenberger's project, Identifying therapeutic targets that sensitize AML to epigenetic therapies, is under the guidance of Dr. Raoul Tibes, an Associate Investigator in TGen's Clinical Translational Research Division and Director of the Hematological Malignancies Program for TGen Clinical Research Service at Scottsdale Healthcare.
Dr. Bogenberger is a member of TGen's Leukemia Research Team, led by Dr. Tibes, which is working to translate state-of-the-art biomedical research into novel targeted therapy approaches for leukemia patients in Arizona. Dr. Bogenberger's fellowship project, which starts July 1, is a collaboration between TGen and a research team at the Mayo Clinic, led by Dr. A. Keith Stewart.
"We are hopeful about the prospects of further investigation and the potential of translating our findings into the clinic,'' said Dr. Bogenberger, who received his doctorate in Cell and Molecular Biology from Colorado State University. "We look forward to demonstrating the merit of our work."
A congratulatory letter from the American Cancer Society to Dr. Bogenberger said, "Your selection resulted from a very rigorous review process intended to fund only the best science and the best scientists and professionals."
AML, which is neither contagious nor inherited, develops through a defect in the immature cells of bone marrow. Although the exact cause is unknown, AML has been linked to prior chemotherapy exposure, benzene exposure and cigarette smoking. Fewer than 10 percent of patients live beyo
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute